Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLAT-07: CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma
NCT04571138Phase 2Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- Sep 2020
- Primary completion
- Aug 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patient-derived CD22-specific CAR T-cells expressing EGFRt in leukemia and lymphoma, sponsored by Seattle Children's. Primary endpoints: Dose Limiting Toxicities at 28 days, Ability to Successfully Manufacture SCRI-CAR22v2 at 28 days and 1 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
patient-derived CD22-specific CAR T-cells expressing EGFRt
03
Conditions
leukemialymphoma
Beyond the preview
Go deeper on NCT04571138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571138.